Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: A meta-analysis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Chen, Han ^a   Yu, Ke Da ^b   Xu, Ge Zhi ^a  

^a EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; COMPLEMENT FACTOR H; CYSTEINE; HISTIDINE; RANIBIZUMAB; THREONINE; TYROSINE;

ARTICLE; COMLEMENT FACTOR H GENE; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHOTODYNAMIC THERAPY; PREDICTION; RETINA MACULA AGE RELATED DEGENERATION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ALLELES; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT FACTOR H; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HOMOZYGOTE; HUMANS; MACULAR DEGENERATION; MODELS, STATISTICAL; ODDS RATIO; PHOTOCHEMOTHERAPY; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865049405     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042464     Document Type: Article

References (30)

1. Yachimski P, Puricelli WP, Nishioka NS, ((2009)) Patient predictors of histopathologic response after photodynamic therapy of Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc 69:: 205--212.
2. Ting AY, Lee TK, MacDonald IM, ((2009)) Genetics of age-related macular degeneration. Curr Opin Ophthalmol 20:: 369--376.
3. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, et al. ((2005)) Complement factor H variant increases the risk of age-related macular degeneration. Science 308:: 419--421.
4. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, et al. ((2005)) Complement factor H polymorphism in age-related macular degeneration. Science 308:: 385--389.
5. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, et al. ((2005)) Complement factor H polymorphism and age-related macular degeneration. Science 308:: 421--424.
6. Laine M, Jarva H, Seitsonen S, Haapasalo K, Lehtinen MJ, et al. ((2007)) Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 178:: 3831--3836.
7. Cheung CM, Tai ES, Kawasaki R, Tay WT, Lee JL, et al. ((2011)) Prevalence of and Risk Factors for Age-Related Macular Degeneration in a Multiethnic Asian Cohort. Arch Ophthalmol.
8. Ding X, Patel M, Chan CC, ((2009)) Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 28:: 1--18.
9. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr, ((2009)) Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 93:: 610--613.
10. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, et al. ((2007)) Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114:: 2168--2173.
11. Seitsonen SP, Jarvela IE, Meri S, Tommila PV, Ranta PH, et al. ((2007)) The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration. Eur J Ophthalmol 17:: 943--949.
12. Klein ML, Francis PJ, Rosner B, Reynolds R, Hamon SC, et al. ((2008)) CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 115:: 1019--1025.
13. Feng X, Xiao J, Longville B, Tan AX, Wu XN, et al. ((2009)) Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology 116:: 1908--1912 e1901.
14. Kloeckener-Gruissem B, Barthelmes D, Labs S, Schindler C, Kurz-Levin M, et al. ((2011)) Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 52:: 4694--4702.
15. Nischler C, Oberkofler H, Ortner C, Paikl D, Riha W, et al. ((2011)) Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol 89:: e344--349.
16. Tsuchihashi T, Mori K, Horie-Inoue K, Gehlbach PL, Kabasawa S, et al. ((2011)) Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. Ophthalmology 118:: 93--100.
17. McKibbin M, Ali M, Bansal S, Baxter PD, West K, et al. ((2012)) CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 96:: 208--212.
18. Orlin A, Hadley D, Chang W, Ho AC, Brown G, et al. ((2012)) Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 32:: 4--9.
19. Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, et al. ((2012)) Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 119:: 571--580.
20. Thakkinstian A, McKay GJ, McEvoy M, Chakravarthy U, Chakrabarti S, et al. ((2011)) Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol 173:: 1365--1379.
21. Zhou P, Fan L, Yu KD, Zhao MW, Li XX, ((2011)) Toll-like receptor 3 C1234T may protect against geographic atrophy through decreased dsRNA binding capacity. FASEB J 25:: 3489--3495.
22. Goverdhan SV, Hannan S, Newsom RB, Luff AJ, Griffiths H, et al. ((2008)) An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye (Lond) 22:: 849--854.
23. Brantley MA Jr, Edelstein SL, King JM, Plotzke MR, Apte RS, et al. ((2009)) Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Eye (Lond) 23:: 626--631.
24. Imai D, Mori K, Horie-Inoue K, Gehlbach PL, Awata T, et al. ((2010)) CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. J Ocul Biol Dis Infor 3:: 53--59.
25. Teper SJ, Nowinska A, Pilat J, Palucha A, Wylegala E, ((2010)) Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 16:: 2598--2604.
26. Yu KD, Shao ZM, ((2011)) Inspection of a deviation from Hardy-Weinberg equilibrium in familial breast cancer cases from a case-control study in a meta-analysis. Breast Cancer Res Treat 127:: 577--579.
27. Ziegler A, Van Steen K, Wellek S, ((2011)) Investigating Hardy-Weinberg equilibrium in case-control or cohort studies or meta-analysis. Breast Cancer Res Treat 128:: 197--201.
28. Skerka C, Lauer N, Weinberger AA, Keilhauer CN, Suhnel J, et al. ((2007)) Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol 44:: 3398--3406.
29. Mori K, Horie-Inoue K, Gehlbach PL, Takita H, Kabasawa S, et al. ((2010)) Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population. Ophthalmology 117:: 928--938.
30. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. ((2000)) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:: 2008--2012.